Elicera Therapeutics
3.04
SEK
+8.57 %
Less than 1K followers
ELIC
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
+8.57%
+28.81%
+82.04%
+82.04%
+90.6%
+110.38%
-24%
-
-50.97%
Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses.
Read moreMarket cap
147.55M SEK
Turnover
1.49M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
15/5
2025
General meeting '25
15/5
2025
Interim report Q1'25
29/8
2025
Interim report Q2'25
All
Research
Press releases
3rd party
ShowingAll content types
Elicera Therapeutics beslutar om ersättningsemission till garanter i samband med att nyttjandeperioden för teckningsoptioner av serie TO2 löpt ut
Teckningsoptioner av serie TO2 i Elicera Therapeutics AB nyttjades till cirka 96,3 procent och bolaget genomför en riktad emission till garanter
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools